vaccines

MDPI

*Review*

# Plant-Based Vaccines in Combat against Coronavirus Diseases

**Benita Ortega-Berlanga * and Tomasz Pniewski**

Institute of Plant Genetics, Polish Academy of Sciences, Strzeszyńska 34, 60-479 Poznań, Poland; tpni@igr.poznan.pl

* Correspondence: bort@igr.poznan.pl

**Abstract:** Coronavirus (CoV) diseases, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) have gained in importance worldwide, especially with the current COVID-19 pandemic caused by SARS-CoV-2. Due to the huge global demand, various types of vaccines have been developed, such as more traditional attenuated or inactivated viruses, subunit and VLP-based vaccines, as well as novel DNA and RNA vaccines. Nonetheless, emerging new COVID-19 variants are necessitating continuous research on vaccines, including these produced in plants, either via stable expression in transgenic or transplastomic plants or transient expression using viral vectors or agroinfection. Plant systems provide low cost, high scalability, safety and capacity to produce multimeric or glycosylated proteins. To date, from among CoVs antigens, spike and capsid proteins have been produced in plants, mostly using transient expression systems, at the additional advantage of rapid production. Immunogenicity of plant-produced CoVs proteins was positively evaluated after injection of purified antigens. However, this review indicates that plant-produced CoVs proteins or their carrier-fused immunodominant epitopes can be potentially applied also as mucosal vaccines, either after purification to be administered to particular membranes (nasal, bronchus mucosa) associated with the respiratory system, or as oral vaccines obtained from partly processed plant tissue.

**Keywords:** coronaviruses; COVID-19; MERS-CoV; SARS-CoV; biopharming; plant-based vaccines



**Citation:** Ortega-Berlanga, B.; Pniewski, T. Plant-Based Vaccines in Combat against Coronavirus Diseases. *Vaccines* **2022**, *10*, 138. https://doi.org/10.3390/vaccines10020138

Academic Editor: Sankar Basu

Received: 4 December 2021
Accepted: 14 January 2022
Published: 18 January 2022



## 1. Introduction

Coronaviruses (CoVs) are clinically relevant pathogens that infect humans, livestock, mice, birds and many other wild animals [1]. They cause localized infections in the respiratory and/or intestinal tracts, in the liver and the central nervous system of their hosts [2]. They belong to the order *Nidovirales*, the family *Coronaviridae*. Based on phylogenetic analysis, CoVs are divided into four genera: the alpha, beta, gamma, and delta coronaviruses [2]. This family of viruses has gained in clinical relevance since 2003, when a new human coronavirus (SARS-CoV-1) was responsible for Severe Acute Respiratory Syndrome (SARS). Later in 2012, a new outbreak of another coronavirus (MERS-CoV) emerged in Saudi Arabia, causing Middle East Respiratory Syndrome (MERS) [3,4]. Most recently, in December 2019 in Wuhan, the Hubei Province, China, the pathogen responsible for a mysterious pneumonia was identified as SARS-CoV-2 and defined as the causal agent of Coronavirus Disease 2019 (COVID-19) [5]. Due to the rapid spread of the virus around the world, COVID-19 was declared to be a pandemic by the World Health Organization (WHO) in March 2020. The origin of this outbreak was associated with the Wuhan Wholesale Seafood Market, where not only seafood is traded, but also exotic fauna [6]. Due to the fact that the greatest diversity of CoVs has been found in bats [7], the hypothesis has been proposed that more recent CoV introductions to humans were originally bat viruses that propagate to an intermediate host (e.g., the Himalayan palm civet for SARS-CoV-1 and the dromedary camel for MERS-CoV), which then exposed humans to the viruses. According to the WHO, the SARS-CoV-1 pandemic affected 8096 people while the MERS pandemic affected 2494 people, with a fatality rate of 9.19% and 34.4%, respectively [8]. Until November 2021,

## 6. Conclusions

Pandemics will generate simultaneous demand for vaccines around the world. Therefore, the use of different platforms for the production of safe and effective vaccines is desirable in order to meet global demand. In this sense, the advantages of plant-based platforms such as low cost, speed, scalability, and safety could help to cover the global demand. However, knowledge of the use of plant expression systems for vaccine production should be more widely disclosed to promote their adoption by governments or private companies in prospect to increase the global health; especially in developing and low-income countries. Discussions with global stakeholders about organizing and financing large-scale vaccine manufacturing, procurement, and delivery are required.

**Author Contributions:** Conceptualization, B.O.-B. and T.P.; investigation, B.O.-B.; writing—original draft preparation, B.O.-B.; writing—review and editing, T.P.; visualization, B.O.-B. and T.P.; supervision, T.P. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Acknowledgments:** The authors are grateful to Anna Binczarowska, Poznań University of Life Sciences, for careful review and language correction of the manuscript.

**Conflicts of Interest:** The authors declare that they have no conflicts of interest.

## References

1. Chen, Y.; Liu, Q.; Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J. Med. Virol.* **2020**, *92*, 418–423. [CrossRef]
2. Fehr, A.R.; Perlman, S. Coronaviruses: An Overview of Their Replication and Pathogenesis. *Methods Mol. Biol.* **2015**, *1282*, 1–23. [CrossRef]
3. Snijder, E.J.; van der Meer, Y.; Zevenhoven-Dobbe, J.; Onderwater, J.J.M.; van der Meulen, J.; Koerten, H.K.; Mommaas, A.M. Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex. *J. Virol.* **2006**, *80*, 5927–5940. [CrossRef] [PubMed]
4. Cauchemez, S.; Van Kerkhove, M.D.; Riley, S.; Donnelly, C.A.; Fraser, C.; Ferguson, N.M. Transmission scenarios for middle east respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart. *Euro. Surveill.* **2013**, *18*, 20503. [CrossRef]
5. Ludwig, S.; Zarbock, A. Coronaviruses and SARS-CoV-2: A Brief Overview. *Anesth. Analg.* **2020**, *30*, 93–96. [CrossRef]
6. Tian, X.; Li, C.; Huang, A.; Xia, S.; Lu, S.; Shi, Z.; Lu, L.; Jiang, S.; Yang, Z.; Wu, Y.; et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg. Microbes Infect.* **2020**, *9*, 382–385. [CrossRef]
7. Drexler, J.F.; Corman, V.M.; Drosten, C. Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. *Antiviral Res.* **2014**, *101*, 45–56. [CrossRef]
8. Prompetchara, E.; Ketloy, C.; Palaga, T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pac. J. Allergy Immunol.* **2020**, *38*, 1–9. [CrossRef] [PubMed]
9. Weekly Epidemiological Update on COVID-19—30 November 2021. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-November-2021 (accessed on 30 November 2021).
10. Masters, P.S. The molecular biology of coronaviruses. *Adv. Virus Res.* **2006**, *66*, 193–292. [PubMed]
11. Ziebuhr, J. The coronavirus replicase. *Curr. Top. Microbiol. Immunol.* **2005**, *287*, 57–94. [CrossRef]
12. De Diego, M.L.; Nieto-Torres, J.L.; Jimenez-Guardeño, J.M.; Regla-Nava, J.A.; Castaño-Rodriguez, C.; Fernandez-Delgado, R.; Usera, F.; Enjuanes, L. Coronavirus virulence genes with main focus on SARS-CoV envelope gene. *Virus Res.* **2014**, *194*, 124–137. [CrossRef]
13. Nal, B.; Chan, C.; Kien, F.; Siu, L.; Tse, J.; Chu, K.; Kam, J.; Staropoli, I.; Crescenzo-Chaigne, B.; Escriou, N.; et al. Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. *J. Gen. Virol.* **2005**, *86*, 1423–1434. [CrossRef] [PubMed]
14. Neuman, B.W.; Kiss, G.; Kunding, A.H.; Bhella, D.; Baksh, M.F.; Connelly, S.; Droese, B.; Klaus, J.P.; Makino, S.; Sawicki, S.G.; et al. A structural analysis of M protein in coronavirus assembly and morphology. *J. Struct. Biol.* **2011**, *174*, 11–22. [CrossRef]
15. De Diego, M.L.; Álvarez, E.; Almazán, F.; Rejas, M.T.; Lamirande, E.; Roberts, A.; Shieh, W.-J.; Zaki, S.R.; Subbarao, K.; Enjuanes, L. A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In Vivo. *J. Virol.* **2007**, *81*, 1701–1713. [CrossRef] [PubMed]
16. Luan, J.; Lu, Y.; Jin, X.; Zhang, L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. *Biochem. Biophys. Res. Commun.* **2020**, *526*, 165–169. [CrossRef] [PubMed]
17. Hamming, I.; Timens, W.; Bulthuis, M.L.C.; Lely, A.T.; Navis, G.J.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **2004**, *203*, 631–637. [CrossRef]